ARWR
Arrowhead Pharmaceuticals, Inc.
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
CUSIP: 04280A100HealthcareUS1 holder
Total Value
$538.9K
Total Shares
6.6K
Net Share Change
+6.6K
Activity
1 buying
Investor
Value
Shares
Weight
Change
